FLOWBONE is involved in the development and promotion of a revolutionary biomaterial for the minimal-invasive augmentation of fragile bones at high risk of fracture. FLOWBONE, follows a completely new treatment approach allowing fragilized bone to strengthen itself without impeding bone mechanics or blood flow within the bone. Our initial focus will be the secondary prevention of hip fractures, fractures that are linked to a high mortality, morbidity and economic burden. The technology is the result of 6+ years of research at EPFL is currently in the pre-clinical phase preparing for clinical trials prior to market commercialization.
Ajouter un commentaire